Physician profile
Noah Moss
NPI 1790063493
$44,195.18
in general payments reported to CMS, 2019-2025
28 companies · $28K in 2025
The $28K reported for 2025 was more than what 97% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,064 · 2020: $1,685 · 2021: $2,873 · 2022: $3,601 · 2023: $3,599 · 2024: $3,677 · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Food and Beverage: $8,836 · Consulting Fee: $1,880 · Travel and Lodging: $1,037 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,200.00 |
| Food and Beverage | $8,836.17 |
| Consulting Fee | $1,880.00 |
| Travel and Lodging | $1,036.59 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $25,967.99 | 2022-2025 | Camzyos |
| Abbott Laboratories | $11,770.52 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $2,024.18 | 2021-2024 | Lifevest |
| Abiomed | $627.63 | 2022-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $570.31 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $486.11 | 2021-2025 | Farxiga, Wainua, Lokelma |
| Boston Scientific Corporation | $426.59 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $277.70 | 2023-2025 | Onpattro, Amvuttra |
| Endotronix, INC. | $240.40 | 2022 | |
| Cvrx, INC. | $223.39 | 2022-2025 | Barostim Neo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $218.82 | 2021-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $197.06 | 2021-2024 | Verquvo, Winrevair |
| Lexicon Pharmaceuticals, INC. | $193.64 | 2023-2024 | Inpefa |
| Scpharmaceuticals INC. | $182.97 | 2023-2025 | |
| Novo Nordisk INC | $167.64 | 2021-2025 | Wegovy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $124.21 | 2022-2025 | |
| Impulse Dynamics (USA) INC. | $109.26 | 2024-2025 | Optimizer |
| Philips North America LLC | $86.65 | 2024-2025 | (Ck4) Mcot, Mcot |
| Heartflow, INC. | $42.03 | 2025 | |
| Eurofins Viracor, LLC | $41.02 | 2021-2023 | |
| Briohealth Solutions, INC. | $40.11 | 2025 | Briovad |
| Cardiva Medical, INC. | $38.28 | 2023 | Cardiva Vascade 5f Vcs |
| Bayer Healthcare Pharmaceuticals INC. | $37.91 | 2022-2024 | |
| Kiniksa Pharmaceuticals International, Plc | $32.72 | 2024 | Arcalyst |
| Amgen INC. | $26.38 | 2022 | |
| Daiichi Sankyo INC. | $23.36 | 2023 | Injectafer |
| Lilly USA, LLC | $18.30 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noah Moss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.